Actym Therapeutics
PrivateLast Round
Series A
Extension
Oct 18, 2023
Total Funding Raised
$70.74M
Company Overview
Actym Therapeutics is a biotechnology company that develops innovative immunotherapy platforms aimed at overcoming the challenging tumor immune microenvironment to provide lasting benefits for cancer patients.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Actym Therapeutics Comparables
Compare Actym Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GenCirq, Inc. | 85% | |
| Salspera, Inc. | 83% | |
| Prokarium | 82% | |
Actym Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Oct 18, 2023 | ||||
| Series A | Jun 28, 2023 | ||||
| Series A | Apr 27, 2020 |
Key People
Founding team and executive leadership
Actym Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Boehringer Ingelheim | Series A, Series A Extension |
| Korea Investment Partners | Series A |
| Boehringer Ingelheim Venture Fund | Series A Extension, Series A |
| Panacea Venture Healthcare | Series A, Series A Extension |
| Korea Investment Partners | Series A |
| Korea Investment Partners | Series A |
| Illumina Ventures | Series A, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 27, 2020
$34M round led by Boehringer Ingelheim and Panacea Venture Healthcare.
Actym Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Actym Therapeutics's valuation, stock price, and market status.